PlaqueTec raised $5 million in an oversubscribed financing round to support its coronary artery disease biomarker effort. The company is running a clinical trial called BIOPATTERN designed to identify blood-based protein biomarkers of inflammation tied to CAD by sampling proteins directly at plaque formation sites. PlaqueTec said proteomic and clinical data from the trial are being used to build BioCarta, an intracoronary data asset intended for drug target selection and patient stratification. The company also said it plans to continue discussions with pharmaceutical and biotech partners. The financing indicates early-stage investor appetite for differentiation in cardiovascular proteomics—especially methods that aim to produce “location-relevant” data rather than relying on conventional blood sampling alone.